The filoviruses and arenaviruses are NIAID/CDC Category A biodefense pathogens that cause severe and rapidly progressing hemorrhagic fever. There are currently no FDA-approved, specific therapeutics against any of these viruses. Investigators in this consortium have recently demonstrated that monoclonal antibodies can provide effective post-exposure protection against these viruses in two or more animal models. Provision of monoclonal antibody immunotherapeutics provides the most economically viable and scientifically proven avenue for pre- or post-exposure therapy. In the armamentarium of this consortium are hundreds of mAbs against these viruses, representing the largest array of antibodies against these viruses yet compiled and including the most effective antibodies known against these viruses. However, we do not what the epitopes of most of these antibodies are, how they function to ameliorate viral infection, or if the currently chosen cocktails are even synergistic. Further, it is largely unknown what sites of the viral glycoproteins are the best targets for antibody intervention. In order to develop these antibodies or cocktails of antibodies for clinical use, we must understand where each antibody binds, which bind to the same or different sites, and which are synergistic and why. This Core (Core D, Mechanistic Structural Biology) will answer these critical knowledge gaps. In this Gore, we are using innovative, state-of-the-art, high-throughput approaches that will allow structural mapping of -100 antibody binding sites per year by single particle electron microscopy. Using these approaches, we will be able to map the epitopes of nearly every anti-filovirus and antiarenavirus antibody known. We will complement these EM approaches by higher-resolution X-ray crystallographic analysis of a smaller set of antibodies of very high interest, chosen for their unique functional capacity and highest efficacy. This information will be used to sort antibodies into groups based on binding site and function. By sorting antibodies into binding site groups, and by integrating essential functional information from the complementary Mechanistic Virology Gore (Core C), we will be able to sort and rank antibodies of each type. We will be able to select the most effective antibodies that bind to each site and determine which combinations among them are most effective. The innovative and state-of-the-art structural studies in this Core will provide information critical to selection and development of the necessary cocktails of antibodies against these emerging and re-emerging public health threats.

Public Health Relevance

This Mechanistic Structural Biology core (Gore D) will map the binding sites of nearly every antibody known to be effective against the highly lethal filovirus and arenavirus families. This work will provide information essential to development of cocktails of antibodies for emergency pre- and post-exposure treatment

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
La Jolla
United States
Zip Code
Liu, Guodong; Wong, Gary; Su, Shuo et al. (2017) Clinical Evaluation of Ebola Virus Disease Therapeutics. Trends Mol Med 23:820-830
Wong, Gary; Mendoza, Emelissa J; Plummer, Francis A et al. (2017) From bench to almost bedside: the long road to a licensed Ebola virus vaccine. Expert Opin Biol Ther :1-15
Hofmann, Daniel; Lai, Jonathan R (2017) Exploring Human Antimicrobial Antibody Responses on a Single B Cell Level. Clin Vaccine Immunol 24:
Nyakatura, Elisabeth K; Soare, Alexandra Y; Lai, Jonathan R (2017) Bispecific antibodies for viral immunotherapy. Hum Vaccin Immunother 13:836-842
Zhao, Xuelian; Howell, Katie A; He, Shihua et al. (2017) Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell 169:891-904.e15
Mire, Chad E; Geisbert, Joan B; Borisevich, Viktoriya et al. (2017) Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med 9:
He, Jing; Melnik, Lilia I; Komin, Alexander et al. (2017) Ebola Virus Delta Peptide is a Viroporin. J Virol :
Fausther-Bovendo, H; Qiu, X; McCorrister, S et al. (2017) Ebola virus infection induces autoimmunity against dsDNA and HSP60. Sci Rep 7:42147
Wec, Anna Z; Herbert, Andrew S; Murin, Charles D et al. (2017) Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses. Cell 169:878-890.e15
Kroeker, Andrea; He, Shihua; de La Vega, Marc-Antoine et al. (2017) Characterization of Sudan Ebolavirus infection in ferrets. Oncotarget 8:46262-46272

Showing the most recent 10 out of 42 publications